Mohamed Sharief
Research Subjects
Mohamed Sharief has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Ammar
Department of Cardiology Worcestershire Acute Hospitals NHS Trust Worcester UK
2 shared publications - Ahmed Muhammed
Cardiology Department , Faculty of Medicine Abbassia, Cairo 1181, Egypt
1 shared publication - Khalid Sawalha
Department of Cardiovascular Medicine Division of Cardiovascular Medicine Baystate Medical Center University of Massachusetts‐Baystate Springfield Massachusetts USA
1 shared publication - Mohamed Abdelazeem
UMass Chan-Baystate Medical Centre, Springfield, USA
1 shared publication - Mohammad Gamal Elewa
Cardiology department, Faculty of Medicine, Ain Shams University , Cairo
1 shared publication - Sabbir Ahmed
Department of Cardiology Worcestershire Acute Hospitals NHS Trust Worcester UK
1 shared publication
Latest Publications
- Open Access
- 21 August 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4) , e70449
Imaging‐Guided Versus Conventional Ventricular Tachycardia Ablation in Ischemic Cardiomyopathy: A Systematic Review and Meta‐Analysis
Advanced cardiac imaging can characterize infarct substrate and guide ablation strategy and lesion delivery during ventricular tachycardia (VT) ablation, but its incremental benefit over conventional strategies in ischemic cardiomyopathy (ICM) remains uncertain. We compared imaging‐guided with conventional VT ablation in adults with ICM. This PRISMA‐compliant systematic review and meta‐analysis was registered in PROSPERO (CRD420261399180). MEDLINE, Cochrane CENTRAL, and Scopus were searched from January 1, 2016, through May 21, 2026, with citation tracking. Comparative analyses were restricted to ICM populations or extractable ICM subgroups. The primary outcome was VT recurrence, pooled using random‐effects risk ratios (RRs); single‐arm imaging‐guided cohorts were summarized descriptively. Four comparative studies included 316 patients, of whom 134 underwent imaging‐guided ablation and 182 underwent conventional ablation. Imaging‐guided ablation was associated with lower VT recurrence (pooled RR 0.53, 95% confidence interval 0.36–0.79; p = 0.002; I 2 = 0%), with consistent effects across imaging modalities and study designs. Major complications were infrequent and numerically similar between groups, although sparse events and heterogeneous definitions precluded pooling. Three additional single‐arm imaging‐guided studies reported favorable VT‐free or event‐free survival, acceptable safety, and high acute non‐inducibility, but were not used to infer comparative efficacy. In patients with ICM undergoing scar‐related VT ablation, imaging‐guided ablation was associated with lower VT recurrence without an apparent increase in major complications; given the limited comparative evidence, these findings are hypothesis‐generating rather than practice‐changing. Larger multicenter randomized trials are required to confirm the magnitude of benefit and define patient selection, imaging modality, and integration strategy.
- 21 August 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4) , e70449
Open AccessImaging‐Guided Versus Conventional Ventricular Tachycardia Ablation in Ischemic Cardiomyopathy: A Systematic Review and Meta‐Analysis
Advanced cardiac imaging can characterize infarct substrate and guide ablation strategy and lesion delivery during ventricular tachycardia (VT) ablation, but its incremental benefit over conventional strategies in ischemic cardiomyopathy (ICM) remains uncertain. We compared imaging‐guided with conventional VT ablation in adults with ICM. This PRISMA‐compliant systematic review and meta‐analysis was registered in PROSPERO (CRD420261399180). MEDLINE, Cochrane CENTRAL, and Scopus were searched from January 1, 2016, through May 21, 2026, with citation tracking. Comparative analyses were restricted to ICM populations or extractable ICM subgroups. The primary outcome was VT recurrence, pooled using random‐effects risk ratios (RRs); single‐arm imaging‐guided cohorts were summarized descriptively. Four comparative studies included 316 patients, of whom 134 underwent imaging‐guided ablation and 182 underwent conventional ablation. Imaging‐guided ablation was associated with lower VT recurrence (pooled RR 0.53, 95% confidence interval 0.36–0.79; p = 0.002; I 2 = 0%), with consistent effects across imaging modalities and study designs. Major complications were infrequent and numerically similar between groups, although sparse events and heterogeneous definitions precluded pooling. Three additional single‐arm imaging‐guided studies reported favorable VT‐free or event‐free survival, acceptable safety, and high acute non‐inducibility, but were not used to infer comparative efficacy. In patients with ICM undergoing scar‐related VT ablation, imaging‐guided ablation was associated with lower VT recurrence without an apparent increase in major complications; given the limited comparative evidence, these findings are hypothesis‐generating rather than practice‐changing. Larger multicenter randomized trials are required to confirm the magnitude of benefit and define patient selection, imaging modality, and integration strategy.
- Open Access
- 19 May 2022
- Published by Springer Nature in Heart Failure Reviews
- Vol. 28 (1) , 229-240
Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction
Sudden cardiac death (SCD) and significant ventricular arrhythmias in patients with dilated cardiomyopathy (DCM) have been markedly reduced over the last couple of decades as a result of the advances in pharmacological and non-pharmacological treatment. Primary prevention implantable cardioverter-defibrillator (ICD) plays an important role in the treatment of patients at risk of SCD caused by ventricular arrhythmias. However, the arrhythmic risk stratification in patients with DCM remains extremely challenging, and the decision for primary prevention ICD implantation based on left ventricular ejection fraction (LVEF) solely appears to be insufficient. This review provides an update on current evidence for primary prevention ICD implantation, arrhythmic risk stratification, and left ventricular reverse remodeling (LVRR) prediction in patients with DCM in addition to most recent guideline recommendations for primary prevention ICD implantation in DCM patients and a proposed multiparametric algorithm based on arrhythmic risk stratification and left ventricular reverse remodeling (LVRR) prediction to better identify patients who are likely to benefit from primary prevention ICD.
- 19 May 2022
- Published by Springer Nature in Heart Failure Reviews
- Vol. 28 (1) , 229-240
Open AccessPrimary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction
Sudden cardiac death (SCD) and significant ventricular arrhythmias in patients with dilated cardiomyopathy (DCM) have been markedly reduced over the last couple of decades as a result of the advances in pharmacological and non-pharmacological treatment. Primary prevention implantable cardioverter-defibrillator (ICD) plays an important role in the treatment of patients at risk of SCD caused by ventricular arrhythmias. However, the arrhythmic risk stratification in patients with DCM remains extremely challenging, and the decision for primary prevention ICD implantation based on left ventricular ejection fraction (LVEF) solely appears to be insufficient. This review provides an update on current evidence for primary prevention ICD implantation, arrhythmic risk stratification, and left ventricular reverse remodeling (LVRR) prediction in patients with DCM in addition to most recent guideline recommendations for primary prevention ICD implantation in DCM patients and a proposed multiparametric algorithm based on arrhythmic risk stratification and left ventricular reverse remodeling (LVRR) prediction to better identify patients who are likely to benefit from primary prevention ICD.